Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Athira Pharma Inc (ATHA)

Athira Pharma Inc (ATHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,518
  • Shares Outstanding, K 38,327
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,670 K
  • 60-Month Beta 2.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.71
Trade ATHA with:

Options Overview Details

View History
  • Implied Volatility 83.67% ( -49.56%)
  • Historical Volatility 115.07%
  • IV Percentile 48%
  • IV Rank 11.21%
  • IV High 627.00% on 03/28/24
  • IV Low 15.10% on 03/15/24
  • Put/Call Vol Ratio 7.61
  • Today's Volume 465
  • Volume Avg (30-Day) 270
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 5,061
  • Open Int (30-Day) 3,849

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.80
  • Number of Estimates 1
  • High Estimate -0.80
  • Low Estimate -0.80
  • Prior Year -0.73
  • Growth Rate Est. (year over year) -9.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.02 +1.88%
on 04/15/24
2.83 -27.08%
on 03/28/24
-0.56 (-21.37%)
since 03/15/24
3-Month
2.02 +1.88%
on 04/15/24
4.30 -52.08%
on 02/21/24
-0.94 (-31.33%)
since 01/12/24
52-Week
1.33 +54.89%
on 11/09/23
4.30 -52.08%
on 02/21/24
-0.51 (-19.84%)
since 04/14/23

Most Recent Stories

More News
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1

Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.

MRK : 126.19 (+0.36%)
IOVA : 11.89 (-3.80%)
ALLO : 3.55 (-6.58%)
ATHA : 2.06 (-15.57%)
Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View

Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.

NVAX : 4.12 (-3.74%)
LGND : 79.77 (-1.95%)
ALLO : 3.55 (-6.58%)
ATHA : 2.06 (-15.57%)
Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock?

Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ATHA : 2.06 (-15.57%)
Johnson & Johnson: Taking The Bull By The Horns?

Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.

JNJ : 147.59 (+0.05%)
ABBV : 161.67 (-0.38%)
ATHA : 2.06 (-15.57%)
ASND : 145.23 (-0.55%)
AZN : 68.73 (-0.29%)
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...

ATHA : 2.06 (-15.57%)
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022

Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron culturesNew orally available small...

ATHA : 2.06 (-15.57%)
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022

BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...

ATHA : 2.06 (-15.57%)
Why Athira Pharma Stock Imploded Today

Its mid-stage clinical trial failed to help patients with Alzheimer's.

ATHA : 2.06 (-15.57%)
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and...

ATHA : 2.06 (-15.57%)
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...

ATHA : 2.06 (-15.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Athira Pharma Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira Pharma Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 2.82
2nd Resistance Point 2.65
1st Resistance Point 2.36
Last Price 2.06
1st Support Level 1.89
2nd Support Level 1.73
3rd Support Level 1.43

See More

52-Week High 4.30
Fibonacci 61.8% 3.16
Fibonacci 50% 2.81
Fibonacci 38.2% 2.46
Last Price 2.06
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar